Sermonix Pharmaceuticals

Executive Summary

Sermonix Pharmaceuticals is a private biotech company focused on developing lasofoxifene, a novel oral selective estrogen receptor modulator (SERM), for the treatment of postmenopausal women and premenopausal women on ovarian suppression with locally advanced or metastatic ER+/HER2- breast cancer harboring ESR1 mutations. This patient population has limited effective oral options after progression on aromatase inhibitors, with fulvestrant being the standard injectable therapy. Lasofoxifene targets the ESR1 mutation, which confers resistance to many endocrine therapies. The company is currently evaluating lasofoxifene 5 mg versus fulvestrant in a Phase 2 trial, measuring progression-free survival as the primary endpoint. Positive results could position lasofoxifene as a convenient oral alternative, addressing an important unmet need. Sermonix is privately held and based in Columbus, Ohio, with limited public information available beyond its lead program.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 PFS Data Readout for Lasofoxifene vs Fulvestrant60% success
• Q4 2026FDA End-of-Phase 2 Meeting Outcomes70% success
• TBDPotential Partnership or Licensing Agreement40% success